The US FDA has extended its approval for AstraZeneca’s acalabrutinib to include initial treatment of mantle cell lymphoma (MCL) in adults who cannot undergo a hematopoietic stem cell transplant. MCL is a rare, aggressive blood cancer and acalabrutinib, sold as Calquence, is the first of its kind approved as front-line therapy for the disease. The drug already had accelerated approval for adults whose MCL had failed at least one prior treatment.

400+ SAP NetWeaver Devices Vulnerable to 0-Day Attacks that Exploited in the Wild
Shadow Servers have identified 454 vulnerable SAP NetWeaver systems affected by a critical zero-day flaw, CVE-2025-31324, allowing unauthenticated file uploads and potential system compromise. Discovered